Phaseline

Targets › IMPDH1

IMPDH1 (Inosine-5'-monophosphate dehydrogenase 1): drug programs, companies and trials

4 programs from 4 companies in 23 trials: 8 Phase 4, 8 Phase 2, 5 Phase 1, 2 Phase 3; Genitourinary, Infectious disease, Oncology; next expected readout Nov 2026.

Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore plays an important role in the regulation of cell growth. Could also have a single-stranded nucleic acid-binding activity and could play a role in RNA and/or DNA metabolism. (UniProt, P20839)

Open in Phaseline: the race on IMPDH1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Chong Kun Dang PharmaceuticalMycophenolate Mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 4Kidney Transplantation; Hypersensitivity Pneumonitis; Liver Transplantation; Lupus Nephritis …Nov 2026
Mats HeymanThioguanine
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 3Leukemia, Acute LymphoblasticJun 2033
RocheMycophenolate Mofetil
Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
IMPDH1, IMPDH2Phase 3Childhood Idiopathic Nephrotic Syndrome–
University of OxfordRibavirin
Inosine-5'-monophosphate dehydrogenase 1 inhibitor; RNA-directed RNA polymerase inhibitor
IMPDH1Phase 2Respiratory Syncytial VirusJan 2027

Conditions

Kidney Transplantation (4) Lupus Nephritis (2) Hypersensitivity Pneumonitis (1) Liver Transplantation (1) IgA Nephropathy (1) Systemic Sclerosis With Lung Involvement (1) Acute Myelogenous Leukemia (1) Immune-mediated Hepatitis (1) Lymphoma, Non-Hodgkin (1) Hematological Malignancies (1) Immunodeficiency (1) Graft Versus Host Disease (1)

Modalities

small molecule (2), mixed (2)

Companies

Chong Kun Dang Pharmaceutical (1) Mats Heyman (1) University of Oxford (1) Roche (1)

Related targets

IMPDH2 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.